

## Poster listing *as at 23 November 2022*

Poster number	Paper Title
<b>Pharmacy Practice (APSA) - Wednesday 30 November</b>	
400	<b>A Retrospective, Longitudinal Study of Antibiotic Prescribing at a Western Australian Hospital</b> Zahraa Abbas, Curtin University
401	<b>Enhancing guideline implementability through communication design strategies: A systematic scoping review</b> Steven Agiasotis, The University of Sydney
402	<b>Co-designing the PRIME tool</b> Dr Nagham Ailabouni, The University of Queensland
403	<b>Patient characteristics and experiences with pharmacy immunisation services in New Zealand</b> Dr Mudassir Anwar, University of Otago, New Zealand
404	<b>Impact of partnered pharmacist medication charting on potentially inappropriate medications use</b> Tesfay Mehari Atey, University of Tasmania
405	<b>Telepharmacy: the way of the future?</b> Anna Barwick, The University of Queensland
406	<b>Health and medication related goals of care of older people with polypharmacy</b> Aagam Bordia, The University of Sydney
407	<b>Exploring consumer's perspective of pharmacist delivering COVID-19 vaccinations</b> Tien Bui, University of South Australia
408	<b>COVID-19 and Mental illness: pandemic perceptions and adherence to public health measures.</b> Tien Bui, University of South Australia
409	<b>Development of a survey to evaluate deprescribing guideline dissemination and implementation</b> Chun Hei Justin Cheng, The University of Sydney
410	<b>COVID-19's impact on pharmacy innovation and legislative changes</b> Maria Cooper, University of South Australia
411	<b>Is amoxicillin a suitable antibiotic for home intravenous administration?</b> Dr Petra Czarniak, Curtin University
413	<b>Clinical pharmacists' participation in ward rounds in Australian hospitals: The current practice</b> Assoc Prof Lisa Kalisch Ellett, University of South Australia
414	<b>What is impacting clinical pharmacists' participation in ward rounds?</b> Assoc Prof Lisa Kalisch Ellett, University of South Australia
415	<b>Clinic-based pharmacists: the missing link</b> Vivienne Lim, Sir Charles Gairdner Hospital
416	<b>Pharmacist consultations in hospitalised older surgical patients</b> Jacinta Lin, The University of Sydney
417	<b>Sleep Health Management in Residential Aged Care Facilities</b> Elissar Mansour, The University of Sydney
418	<b>Do entry-level pharmacy students have different personal characteristics?</b> Prof Carlo Marra, University of Otago, New Zealand
419	<b>Predictors of pharmacist's and pharmacy students' involvement in patient-centred pharmacy services</b> Prof Carlo Marra, University of Otago, New Zealand
420	<b>Pharmacy students' role expectations in practice: A comparison between NZ and Canada</b> Prof Carlo Marra, University of Otago, New Zealand
421	<b>Optimising adherence to allopurinol and gout management: people with gout's perspectives</b> Toni Michael, The University of Sydney
422	<b>20 years of obstetric medicines information calls—a timeline of patterns and trends</b> Nabeelah Mukadam, King Edward Memorial Hospital
423	<b>Investigating medicinal cannabis as a treatment for spasticity and muscle spasms</b> Xenia Nastatos, The University of Sydney
424	<b>Are Essential Medicines Accessible?</b> Lachlan Oldfield, The University of Sydney
425	<b>A scoping review of health-system guidelines for opioid dispensing</b> William Olsen, The University of Queensland
426	<b>The codesign and evaluation of an osteoporosis module by teachers and pharmacists</b> Jonathan Phuong, Sydney University
427	<b>The importance of medication information to community dwelling individuals</b> Dr Joy Spark, University of New England

## Pharmacy Practice (APSA) *continued*

428	<b>Pharmacists' acceptability of perinatal depression screening in community pharmacies: A content analysis</b> Clara Strowel, The University of Sydney
429	<b>Prevalence of fluoropyrimidine-induced toxicities in patients receiving fluoropyrimidine-based chemotherapy</b> Dr Vijay Suppiah, University of South Australia
430	<b>Barriers and enablers to the use of parenteral methotrexate: a scoping review</b> Jiun Ming Tan, University of South Australia
431	<b>Evaluation of available medication management resources for carers of people with dementia</b> Gabrielle Widjaja, The University of Sydney
432	<b>Application of user-centred co-design principles to address barriers in therapeutic drug monitoring</b> Sherilyn Wong, University of South Australia
433	<b>Exploring health literacy responsiveness within remote pharmacy organisations</b> Helen Wood, The University of Western Australia
434	<b>Exploring Australian pharmacists' perspectives and attitudes towards the down-scheduling of melatonin</b> Kingston Yeung, The University of Sydney
435	<b>Determination of physical compatibility of oxycodone and co-administered drugs via intra-venous ports</b> Souha Youssef, University of South Australia
436	<b>Psychotropic adverse drug event monitoring tools for residential care: a systematic review</b> Brigid McInerney, Monash University
437	<b>Prevalence and predictors of long-term opioid use following orthopaedic surgery in Australia</b> Dr Jonathan Penm, The University of Sydney
438	<b>Understanding pharmacists' scope of practice in managing asthma in the community</b> Weiqi Wu, The University of Sydney

## Toxicology (ASCEPT) – Thursday 1 November

439	<b>The impact of medicinal cannabis legalisation and re-scheduling on poisonings in Australia</b> Sara Allaf, The University of Sydney
440	<b>Paracetamol (acetaminophen) hepatotoxicity increases in the presence of an added herbal compound</b> Susan Britza, The University of Adelaide
441	<b>Could herbal soup be a potentially unrecognised cause of hepatotoxicity at autopsy?</b> Susan Britza, The University of Adelaide
442	<b>The impact of pharmacist only up-scheduling of modified release paracetamol on poisonings</b> Dr Rose Cairns, The University of Sydney
443	<b>Biochemical changes in liver and intestinal cells induced by weight loss supplements</b> Emily Davies, Murdoch University
444	<b>QSAR models to detect endocrine-disrupting chemicals acting at the retinoic acid receptor</b> Raymond Lui, The University of Sydney
445	<b>Bisphenols depress contractile activity of gut smooth muscle in rats</b> Prof Maloy Bikash Mandal, Banaras Hindu University, India
446	<b>Nitromethane toxicokinetics estimated from a case study</b> Dr Frank Reimann, Hunter New England Local Health District
447	<b>Plastic released toxic chemical delays the gastric emptying time: Experimental evidence</b> Dr Atanu Roy, Banaras Hindu University, India
448	<b>Poisonings in older people with dementia: a systematic scoping review</b> Ilsa Wojt, The University of Sydney
449	<b>Biochanin A and quercetin modulate simvastatin toxicity in HepG2 cultures</b> Joshua Zechner, The University of Adelaide
450	<b>Machine learning exploration of per and poly fluoroalkyl substance (PFAS) toxicity</b> Dr Slade Matthews, The University of Sydney

## Drug Discovery (ASCEPT) - Wednesday 30 November

451	<b>Tumour Microenvironmental Features Direct Stem Cells Fate</b> Arian Ansardamavandi, The University of Melbourne
452	<b>Fragment screening against stabilised <math>\alpha 1A</math>- and <math>\alpha 1B</math>-adrenoceptors identifies novel sub-type selective antagonist</b> Dr Alaa Abdul-Ridha, The Florey Institute of Neuroscience and Mental Health
453	<b>Assessment of glucose-lowering constituents in Teucrium Polium extract</b> Yaser Albadr, Curtin University
454	<b>Validation of positive allosteric modulators for DOR to treat gastrointestinal motility disorders</b> Sadia Alvi, Monash University
455	<b>Gs priming of non-Gs protein activation and signalling at the glucagon-likepeptide-1 receptor</b> John Azieta, Monash University

## Drug Discovery (ASCEPT) *continued*

456	<b>Solving the P2X1 receptor structure – a target for male contraception</b> Felix Bennetts, Monash University
457	<b>Molecular dynamics simulations reveals a novel cholesterol binding site for P2X7 receptors</b> Zheng Chen, The University of Sydney
458	<b>The orexin receptors exhibit spatiotemporal signalling mechanisms in response to endogenous ligands</b> Natasha Dale, Harry Perkins Institute of Medical Research
459	<b>Computational modelling of heterotrimeric P2X7 receptors</b> Sophie De Salis, The University of Sydney
460	<b>Measuring intracellular calcium signalling dynamics between cell-in-cell structures using genetically-encoded calcium indicators</b> Ellen Janke, The University of Queensland
461	<b>Triple negative breast cancer: Screening for the invasion amplifying cAMP-calcium feedforward loop</b> Terrance Lam, Monash University
462	<b>Drug repurposing screen targeting PARP in high grade serous ovarian cancer</b> Bayley Matthews, University of Newcastle
463	<b>Investigating the pharmacological relationship between GPR161 and spexin-1</b> Kinjal Patel, UNSW Sydney
464	<b>Assessment of store operated calcium entry in cellular ageing models</b> Vijayraghavan Seshadri, University of Tasmania
465	<b>Screening assays for inhibitors against SARS-CoV-2 Spike protein and cell entry</b> Dr Pdraig Strappe, Curtin University
466	<b>Antiviral activity of Selective Serotonin reuptake inhibitors against enteroviruses</b> Dr Pdraig Strappe, Curtin University
467	<b>The search for a ligand for the pro-atherosclerotic orphan GPCR, GPR146</b> Brendan Wilkins, UNSW Sydney
468	<b>Quantification of the inhibitory effect of neurofibromin 1 (NF1) using biosensors</b> Michelle Xiaomeng Xu, Monash University
469	<b>Aptamer-based Phenylalanine Sensor for Cell Culture Monitoring</b> Yiling Yang, The University of Melbourne
470	<b>Investigating the atypical DRY motif of the potential lipid-lowering orphan receptor GPR146</b> Jack Zhang, UNSW Sydney
471	<b>The role of RunX2 in calcium-related signaling pathways in breast cancer cells</b> Junkai Zhang, The University of Queensland
472	<b>The influence of soluble microenvironment on tumour cell cytotoxicity of chemotherapeutics</b> Xiaodan Zhang, The University of Melbourne

## Neuropharmacology (ASCEPT) - Wednesday 30 November

473	<b>Polypharmacy with high Drug Burden Index (DBI) reduces function with sex differences</b> Gizem Gemikonakli, The University of Sydney
474	<b>Hypocretin-1 receptor antagonism and inhibitory control during the go/no-go task</b> Assoc Prof Laura Jacobson, Florey Institute of Neuroscience and Mental Health
475	<b>Desensitising Properties of Gain-of-function GABRB3 variants influence the severity of DEE</b> Susan Lin, The University of Sydney
476	<b>Investigating an orexin receptor 2 structure-function relationship with C-terminus mutants</b> Henry Purbrick, Harry Perkins Institute for Medical Research
477	<b>Role of endocannabinoids in fear learning in a murine neuropathic pain model</b> Saima Sadia, The University of Sydney

## Cardiovascular (ASCEPT) - Thursday 1 November

479	<b>Exploring cardiac GPCRs for effective fibrosis treatment</b> Joel Coffie, Monash University
480	<b>Intermittent fasting protects against chronic cerebral hypoperfusion-induced cerebrovascular transcriptomic changes</b> Dr Michael De Silva, La Trobe University
481	<b>Use of oral effective dose 50 (ED50) to optimise antihypertensive drug dose</b> Prof Simon Dimmitt, University of Western Australia
482	<b>Unravelling the intracellular signalling pathways in CGRP-induced vasorelaxation in rat coronary arteries</b> Lucy Donovan, University of Oxford, UK
483	<b>Australian patients' perspectives on oral anticoagulant initiation in atrial fibrillation</b> Eyob Alemayehu Gebreyohannes, University of Western Australia

## Cardiovascular (ASCEPT) *continued*

484	<b>Effects of acute and chronic trimethylamine-N-oxide and simulated diabetes in cardiac myoblasts</b> Saba Naghipour, Griffith University
485	<b>Influence of natriuretic peptides on vasculature– Cell culture for drug testing?</b> Christine Rager, Monash University
486	<b>Sex differences in risk of diabetes-associated cardiovascular events with SGLT2i versus GLP-1RAs</b> Abhipree Sharma, Monash University
487	<b>Antiarrhythmic effects of phenytoin, a novel heart failure diastolic ryanodine channel inhibitor</b> Melanie Spratt, Queensland University of Technology
488	<b>Gene expression analyses of Tas1R taste receptors in cardiometabolic disease</b> Mariah Stavrou, UNSW Sydney
489	<b>Metabolic profiling of mice with deletion of orphan GPCR, GPR37L1</b> Margaret Mouat, UNSW
490	<b>High-definition flow cytometry of the mouse kidney for single cell studies</b> Jake Robertson, La Trobe University
491	<b>Impairment of prostacyclin signalling: impact of ageing and coronary spasm</b> Kate Spuler, The University of Adelaide

## Respiratory and Inflammation (ASCEPT) - Thursday 1 November

492	<b>Challenging the inhibitory/excitatory paradigm: Increased GABAergic inhibition can lead to epilepsy</b> Prof Mary Chebib, The University of Sydney
493	<b>Pirfenidone is more effective than glucocorticosteroids in limiting influenza-A-viral infection and inflammation</b> Julia Chitty, Monash University
494	<b>CXCL17 is a novel MRGPRX2 agonist: Importance of cellular context</b> Jie Ding, The University of Melbourne
495	<b>Adding a dimension to biomechanical cues underlying IPF</b> Avanka Gunatilaka, The University of Melbourne
496	<b>Cell shape: A determinant of TGF-<math>\beta</math> functionality?</b> Chiao Hwei Lee, The University of Melbourne
497	<b>Characterising the contribution of Casein Kinase 1<math>\delta</math> in the fibrogenesis of IPF</b> Stephanie Zhang, The University of Melbourne

## Education (APSA and ASCEPT) - Thursday 1 November

498	<b>Academic student partnership in developing an online workshop to address vaccine hesitancy</b> Dr Suzanne Caliph, Monash University
499	<b>A faculty approach to unify the Honours program in Pharmaceutical Science</b> Dr Betty Exintaris, Monash University
500	<b>Student perceptions of pharmacology laboratory experiences: Computer simulation vs in-person "wet" lab</b> Dr Yeong Hann Ling, Monash University
501	<b>Using clinical case studies to build work relevant skills</b> Dr Suong Ngo, The University of Adelaide
502	<b>Student perspectives on the effects of cognitive enhancers and attitudes towards use</b> Dr Anna-marie Babey, University of New England
503	<b>How do technology-enhanced learning strategies affect biomedical and healthcare students' engagement?</b> Michelle Chen, The University of Sydney
504	<b>Going digital – students' perceptions of electronic laboratory notebooks (ELNs)</b> Dr Betty Exintaris, Monash University

## Pharmacy and Pharmaceutical Sciences Education (APSA) - Thursday 1 November

506	<b>Examining the First Nations cultural safety content in Australian Pharmacy Schools</b> Alexander Burke, The University of Sydney
507	<b>Clinical impact of Antibigrams to optimise antimicrobial prescribing and patient health outcomes</b> Assoc Prof Chris Freeman, The University of Queensland
508	<b>Exploring current teamwork skill aptitudes of first year Pharmaceutical Science undergraduate students</b> Dr Nilushi Karunaratne, Monash University
509	<b>Pharmacy students' health literacy knowledge: A qualitative exploratory study</b> Helen Wood, The University of Western Australia



## Pharmacogenomics (ASCEPT) - Thursday 1 November

510	<b>Non-DPYD gene variants associated with severe fluoropyrimidine toxicity</b> Dr Katie Burns, University of Auckland, New Zealand
511	<b>Pharmacogenomic implications of polypharmacy in hospitalised patients taking antipsychotic medications</b> Dr Vijay Suppiah, University of South Australia
512	<b>Dihydropyrimidine dehydrogenase (DPD) phenotyping methodologies: A literature review</b> Dr Vijay Suppiah, University of South Australia
513	<b>Investigating how polypharmacy and deprescription alter the hepatic proteome in aged mice</b> Kevin Winardi, The University of Sydney
514	<b>Outcomes and popPKs of antiviral drugs used in COVID-19 patients: A review</b> Dr Suong Ngo, The University of Adelaide

## Pharmacoepidemiology (ASCEPT) - Wednesday 30 November

515	<b>The use of psychotropic medication in autistic young people in Western Australia</b> Roselyne Bulonza, Curtin University
516	<b>Prescribing patterns in very elderly patients in Christchurch, New Zealand</b> Assoc Prof Matt Doogue, Te Whatu Ora Waitaha & University of Otago
517	<b>Deprescribing heart failure medications in older people: a systematic review and meta-analysis</b> Mai Duong, The University of Sydney
518	<b>Prescribing of antiviral agents for COVID-19 in a large tertiary hospital</b> Dr Joshua Inglis, Flinders Medical Centre
519	<b>Trends in the utilisation of antiepileptic drugs following ischemic stroke</b> Stella Jung-Hyun Kim, Monash University
520	<b>Prevalence and association of antipsychotic drugs with falls in hospitalised older adults</b> Prof David Le Couteur, Sydney University
521	<b>Trends in incidences and mortality of hip fractures and associated risk factors</b> Miriam Tim Yin Leung, Monash University
522	<b>Medicine use in people with cystic fibrosis before and after modulator therapy</b> Louise Lord, Monash University
523	<b>Can we accurately predict future dementia in middle-aged adults?</b> Dr Gopisankar Mohanannair Geethadevi, Monash University
524	<b>Opioid deprescribing interventions for patients at transitions of care: A scoping review</b> Jeffery Wang, The University of Sydney
525	<b>Audit of data sharing by pharmaceutical companies for anticancer medicines</b> Natansh Modi, Flinders University

## Drug Disposition and Response (ASCEPT) - Wednesday 30 November

526	<b>Between patient variability in drug disposition of large vs small molecules</b> Assoc Prof Hesham Al-Sallami, University of Otago, New Zealand
527	<b>Suppressing resistance of hypermutable Pseudomonas aeruginosa in a dynamic in-vitro biofilm model</b> Siobhonne Breen, Monash University
528	<b>Investigating the phenotypic plasticity of glioblastoma stem cells</b> Willem du Preez, The University of Sydney
529	<b>Using recombinant DNA technology to produce a delivery system for genetic drugs</b> Yuzhang Li, The University of Queensland
530	<b>Metabolic footprinting in a hollow-fibre infection model: Ceftolozane-tazobactam versus Pseudomonas aeruginosa</b> Jessica Tait, Monash University
531	<b>PK/PD indices cannot predict ciprofloxacin versus Pseudomonas aeruginosa with resistance mechanisms outcomes</b> Alice Terrill, Monash University

## Urogenital and Gastrointestinal (ASCEPT) - Wednesday 30 November

533	<b>The effects of sildenafil on porcine distal ureteral contractions</b> Asst Prof Iris Lim, Bond University
534	<b>Severe hyperglycaemia impairs bladder contractility in a murine model of diabetes mellitus</b> Dr Donna Sellers, Bond University
535	<b>Gut dysbiosis in refractory hyperammonaemic syndrome post lung-transplant: Bystander or bad guy?</b> Dr Tess Evans, College of Intensive Care Medicine
536	<b>Aurocyanide is an active metabolite of auranofin for its anti-liver fibrosis effect</b> Prof Keon Wook Kang, Seoul National University, South Korea
537	<b>Global gut sampling: Implementing the ICU Prospective Observational Embedded Microbiome Study (POEMS)</b> Catarina Wylde, University of Western Australia

**Clinical Pharmacology (ASCEPT) - Thursday 1 November**

505	<b>The patient perspective: understanding the breast cancer medication management process</b> Elizabeth Heard, University of New South Wales
538	<b>Serious statin-associated myotoxicity in Indigenous Australians - a literature case series 2010-2020</b> Dr Genevieve Gabb, South Australia Health
539	<b>Development of a PBPK model for Irbesartan in different CYP2C9 genotypes</b> Pureum Kang, Sungkyunkwan University, South Korea
540	<b>PBPK modeling and simulation for glipizide related to CYP2C9 genetic polymorphism</b> Pureum Kang, Sungkyunkwan University, South Korea
541	<b>Preventing urate-lowering therapy induced gout flares: a systematic review and network meta-analysis</b> Dorsa Maher, University of South Australia
542	<b>Development of Plasma Assay for Tyrosine Kinase Inhibitors</b> Angus Mcpherson, University of Newcastle
543	<b>Vanquish the vancomycin trough: the AUC strikes back</b> Marie-Claire Morahan, Te Whatu Ora Waitaha, New Zealand
544	<b>Validated UHPLC-MS/MS assay for quantification of opioids used for cancer pain management</b> Dr Stefan Musolino, The University of Adelaide
545	<b>Inhibition of cancer stem cells of MDA-MB-231 and MCF-7 by phenethyl isothiocyanate</b> Dr Suong Ngo, The University of Adelaide
546	<b>Using electronic prescription and laboratory data to assess prescribing practice</b> Lorna Pairman, University of Otago, New Zealand
547	<b>PBPK modeling of glimepiride in different CYP2C9 genotypes</b> Hyejung Park, Sungkyunkwan University, South Korea
548	<b>PBPK modeling of gliclazide in different CYP2C9 and CYP2C19 genotypes</b> Hyejung Park, Sungkyunkwan University, South Korea
549	<b>Immunosuppressant drug concentrations are assay-specific</b> Dr Frank Reimann, Hunter New England Local Health District
550	<b>Development of medication management guidance resources for people with dementia and carers.</b> Dr Mouna Sawan, The University of Sydney
552	<b>Prospective Study of A Clinical Quality Intervention (SMAART) to identify and challenge children with "low risk" penicillin and cephalosporin</b> Dr Duaa Gaafar, The University of Melbourne
553	<b>Phase 1a/1b trial of a tight junction regulator (IMU-856) for coeliac disease</b> Dr Tom Polasek, Certara
554	<b>Which patients are accessing medicinal cannabis under the Special Access Scheme</b> Dr David Taylor, Eastern Health
555	<b>Vancomycin AUC optimisation using minimal plasma concentration monitoring</b> Assoc Prof Matt Doogue, Te Whatu Ora Waitaha & University of Otago, New Zealand

**Pharmaceutical Science (APSA) - Thursday 1 November**

556	<b>3D printed estradiol buccal film: Design effect on release kinetics</b> Sadikmahdi Hussen Abdella, University of South Australia
557	<b>Development of a novel pH-buffered alginate gel for resistant wound infections</b> Fatima Abid, University of South Australia
558	<b>Fabrication of novel hydrogels from oxidized inulin crosslinked gelatin for drug delivery</b> Dr Franklin Afinjuomo, University of South Australia
559	<b>Triton X-100 alternative surfactants for split-virus influenza vaccine</b> Abdulsalam Alharbi, The University of Sydney
560	<b>Pharmacokinetics of Bee Venom Phospholipase A2 in rats using a sandwich ELISA</b> Soon Uk Chae, The Catholic University of Korea, South Korea
562	<b>Development of PBPK models to predict the effect of rabeprazole on vismodegib</b> Seong Jun Jo, The Catholic University of Korea, South Korea
563	<b>Measurement of P<sub>app</sub> using HiPSC-IECs and prediction pharmacokinetic profiles using PBPK models</b> Chae Bin Lee, The Catholic University of Korea, South Korea
564	<b>New Adjuvants to Bring Back Life to Old Antibacterials - Fosfomycin and Meropenem</b> Elissar Mansour, The University of Sydney
565	<b>Economic and time-efficient method for API extraction from equine pharmaceutical formulations</b> Thabata Muta, University of South Australia
566	<b>Development of remdesivir and ebselen containing inhalable dry powder for COVID-19</b> Tushar Saha, University of Otago, New Zealand
567	<b>Development of LC-MS/MS Analysis for Pergolide in Equine Plasma</b> Dr Yunmei Song, University of South Australia

## Pharmaceutical Science (APSA) *continued*

568	<b>5-fluorouracil and leucovorin predictive pharmacokinetics after administration of standard treatment and Deflexifol™</b> Dr Tahlia Meola, University of South Australia
569	<b>Palmitoylethanolamide (palmidrol) as an analgesic and anti-inflammatory treatment for diabetic-related peripheral neuropathy</b> Emily Pickering, The University of Queensland
570	<b>Pharmacokinetic-pharmacodynamic modeling and simulation in the dosing of methotrexate</b> Jiun Ming Tan, University of South Australia

## Innovation and Industry (ASCEPT) - Thursday 1 November

571	<b>Transcriptome analysis of rapidly maturing CLEFF4 and age matched parent Caco2 cells</b> Dr Andrew Crowe, Curtin University
-----	---